Cargando…
Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer
PURPOSE: To evaluate GT0918, a 2nd-generation AR antagonist, for its AR down-regulation activity among breast cancer patients. METHODS: The effect of GT0918 on AR protein expression was evaluated in AR expression breast cancer cells and in breast cancer xenograft model. A 3 + 3 phase I dose-escalati...
Autores principales: | Li, Huiping, Song, Guohong, Zhou, Qiaoxia, Ran, Ran, Jiang, Hanfang, Zhang, Ruyan, Liu, Yaxin, Zhang, Jiayang, Meng, Luping, Ma, Liandong, Sun, Ye, Wang, Meiyu, Zhou, Qingqing, Yan, Honghua, Zhou, Qianxiang, Dong, Xunwei, Tong, Youzhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505310/ https://www.ncbi.nlm.nih.gov/pubmed/34392453 http://dx.doi.org/10.1007/s10549-021-06345-x |
Ejemplares similares
-
Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023) -
Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022) -
The prognostic value of neutrophil-to-lymphocyte ratio in de novo stage IV breast cancer: a retrospective cohort study
por: Shao, Bin, et al.
Publicado: (2023) -
Bilateral breast cancer in China: A 10‐year single‐center retrospective study (2006–2016)
por: Jiang, Hanfang, et al.
Publicado: (2021) -
Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China
por: Lei, Wen, et al.
Publicado: (2020)